within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A03F_Propulsives.A03FA05_Alizapride;

model Alizapride
  extends Pharmacolibrary.Drugs.ATC.A.A03FA05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A03FA05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Alizapride is a dopamine D2 antagonist antiemetic used for the prevention and treatment of nausea and vomiting, especially associated with chemotherapy, radiotherapy, or post-operative procedures. It is structurally related to metoclopramide but exhibits reduced extrapyramidal side effects. Although not widely marketed today and with approval status ambiguous in many regions, it has been historically used clinically for its antiemetic properties.</p><h4>Pharmacokinetics</h4><p>No primary clinical pharmacokinetic publications could be identified for alizapride in humans. Parameter estimates provided are based on secondary sources and analogy with structurally related drugs (e.g., metoclopramide) and summary data available from regulatory or drug reference compendia.</p><h4>References</h4><ol><li><p>Roché, H, et al., &amp; Desjardins, R (1987). Comparative effects of intravenously administered alizapride and prochlorperazine in cisplatin-induced emesis. <i>Cancer investigation</i> 5(2) 89–93. DOI:<a href=&quot;https://doi.org/10.3109/07357908709018461&quot;>10.3109/07357908709018461</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3607576/&quot;>https://pubmed.ncbi.nlm.nih.gov/3607576</a></p></li><li><p>Houin, G, et al., &amp; Tillement, JP (1984). Absolute intramuscular, oral, and rectal bioavailability of alizapride. <i>Journal of pharmaceutical sciences</i> 73(10) 1450–1453. DOI:<a href=&quot;https://doi.org/10.1002/jps.2600731033&quot;>10.1002/jps.2600731033</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6502497/&quot;>https://pubmed.ncbi.nlm.nih.gov/6502497</a></p></li><li><p>Houin, G, et al., &amp; Tillement, JP (1983). High-performance liquid chromatographic determination of alizapride, a new antiemetic compound, and its application to a dose-dependent pharmacokinetic study. <i>Journal of pharmaceutical sciences</i> 72(1) 71–74. DOI:<a href=&quot;https://doi.org/10.1002/jps.2600720117&quot;>10.1002/jps.2600720117</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6827466/&quot;>https://pubmed.ncbi.nlm.nih.gov/6827466</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Alizapride;
